Volume 3.02 | Jan 20

Mammary Cell News 3.02 January 20, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Study Provides Molecular Rationale For Combining Targeted Agents to Treat Breast Cancer  ShareThis
A new study provides a rationale for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer. [Press release from The Ohio State University discussing online prepublication in Cancer Research]



Facebook  Cell Therapy News is now on Facebook. Join us!

Twitter Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at [email protected]


U-M Researchers Find Indirect Path to Attack Breast Cancer Stem Cells
Scientists have identified a potential new way of attacking breast cancer stem cells. Researchers found that breast cancer stem cells are regulated by mesenchymal stem cells. [Press release from the University of Michigan (U-M) discussing online prepublication in Cancer Research]

Automated Assay Detects Lymph Node Metastases after Breast Cancer
An automated molecular assay that can detect metastatic breast cancer in axillary sentinel lymph nodes during surgery performs comparably to conventional postoperative histologic examination, study findings indicate. [Press release from MedWire News discussing online prepublication in Cancer]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-Beta-Catenin Signaling
Researchers identify a mechanism in which EZH2 expression-mediated downregulation of DNA damage repair leads to accumulation of recurrent RAF1 gene amplification in breast tumor initiating cells (BTICs), which activates p-ERK-beta-catenin signaling to promote BTIC expansion. [Cancer Cell]

Contractility of the Cell Rear Drives Invasion of Breast Tumor Cells in 3D Matrigel
Investigators report that MDA-MB-231 human breast adenocarcinoma cells invade 3D Matrigel with a characteristic rounded morphology and with F-actin and myosin-IIa accumulating at the cell rear in a uropod-like structure. [Proc Natl Acad Sci USA]

Inducible Formation of Breast Cancer Stem Cells and Their Dynamic Equilibrium with Non-Stem Cancer Cells via IL6 Secretion
Tumor heterogeneity involves a dynamic equilibrium between cancer stem cells (CSCs) and nonstem cancer cells mediated by IL6 and activation of the inflammatory feedback loop required for oncogenesis. This dynamic equilibrium provides an additional rationale for combining conventional chemotherapy with metformin, which selectively inhibits CSCs. [Proc Natl Acad Sci USA]

Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
Scientists used in vitro and mouse xenograft models to examine the interaction between breast cancer stem cells and bone marrow-derived mesenchymal stem cells. [Cancer Res]

Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer
Trimethylation of histone 3 lysine 27 is a critical epigenetic mark for the maintenance of gene silencing. Additional accumulation of DNA methylation in target loci is thought to cooperatively support this epigenetic silencing during tumorigenesis. However, molecular mechanisms underlying the complex interplay between the two marks remain to be explored. Investigators demonstrate that activation of PI3K/AKT signaling can be a trigger of this epigenetic processing at many downstream target genes. [Cancer Res]

Kruppel-Like Factor 4 (KLF4) Is Required for Maintenance of Breast Cancer Stem Cells and for Cell Migration and Invasion
Scientists show that KLF4 was highly expressed in cancer stem cell-enriched populations in mouse primary mammary tumor and breast cancer cell lines. [Oncogene]

Targeting the Akt/Mammalian Target of Rapamycin Pathway in Brca1-Deficient Cancers
To further investigate the role of breast cancer susceptibility gene 1 (Brca1)/Akt in tumorigenesis, investigators analyzed Brca1/Akt expression in human breast cancer samples and found that reduced expression of Brca1 was highly correlated with increased phosphorylation of Akt. [Oncogene]

Adipose Derived Stem Cells (ASCs) Isolated from Breast Cancer Tissue Express IL-4, IL-10 and TGF-Beta1 and Upregulate Expression of Regulatory Molecules on T Cells: Do They Protect Breast Cancer Cells from the Immune Response?
Researchers isolated adipose derived stem cells (ASCs) from breast cancer and normal breast tissues to investigate the expressions of IL-4, IL-10 and transforming growth factor (TGF)-beta1 in ASCs and to see if ASCs isolated from patients can modulate the regulatory molecules on peripheral blood lymphocytes. [Cell Immunol]


A Novel Automated Assay for the Rapid Identification of Metastatic Breast Carcinoma in Sentinel Lymph Nodes
The authors prospectively evaluated the performance of a proprietary molecular testing platform using one-step nucleic acid amplification (OSNA) for the detection of metastatic carcinoma in sentinel lymph nodes in a large multicenter trial and compared the OSNA results with the results from a detailed postoperative histopathologic evaluation (reference pathology) and from intraoperative imprint cytology. [Cancer]


Cancer Research UK and Cancer Research Technology Establish Team of Stem Cell Experts to Beat Cancer
Cancer Research UK and its commercial arm Cancer Research Technology, have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer. [Cancer Research UK Press Release]

Genentech Submits Response to FDA’s Notice of Opportunity for a Hearing on Proposal to Withdraw Approval of Metastatic Breast Cancer Indication for Avastin
Genentech, Inc. submitted its response to the U.S. Food and Drug Administration’s (FDA) Notice of Opportunity for a Hearing on the Agency’s proposal to withdraw approval of the metastatic breast cancer indication for Avastin® (bevacizumab). [Genentech, Inc. Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


Visit our events page  to see a complete list of events in the mammary cell community.


Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Post-Doctoral Research Fellow (Bergonie Cancer Institute)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at  no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us